Gisela Gonzalez
Business Development Manager at CIMAB SA
Articles
Manufacturing Process Development for an Epidermal Growth Factor-Based Cancer Vaccine
Beatriz Garcia;Aurora Tamara Garcia;Gryssell Rodriguez;Tania Crombet;Alejandro Portillo;Ariadna Cuevas;Lisel Viña;Gisela Gonzalez;Ernesto Chico;Loany Calvo;Airama Albisa
October 2nd 2008The Center for Molecular Immunology (Havana, Cuba) has been working on a novel cancer immunotherapy targeting the epidermal growth factor (EGF). The vaccine is composed of a chemical conjugate of EGF and a carrier protein (rP64k), designed to trigger an anti-EGF antibody response. The results of studies of molecular characterization, immunogenic activity, and clinical data are presented here.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: November 15th 2024 | Updated: November 20th 2024
Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs
Published: October 28th 2024 | Updated: November 20th 2024
Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems
Published: October 22nd 2024 | Updated: November 20th 2024
Optimizing cGMP Facility Design Space with a Hybrid Approach
Published: October 28th 2024 | Updated: November 20th 2024
Quantifying Chemotherapeutic Cytotoxicity in Glial Cells using AI-Driven Label-Free Cell Analysis
